Molecular Combination of the Dopamine and Serotonin Scaffolds Yield in Novel Antipsychotic Drug Candidates – Characterization by in vivo Experiments

Abstract

Serotonin and dopamine play an important role in the aetiology of schizophrenia. Combination of the structural scaffolds of both neurotransmitters in a single molecule lead to aromatic [d,g]-bisannelated azecine derivatives, which have been shown to be nanomolar to subnanomolar dopamine D₁-D₅ receptor antagonists with a preference for the D₁ family. In this work the potential antipsychotic activity of some azecine derivatives was predicted by their dopamine receptor affinities obtained in vitro from radioligand binding experiments and conclusively confirmed in vivo (rats) by applying a conditioned avoidance model. Furthermore, the compounds were tested in vivo for the development of catalepsy, which is a predictive parameter for extra-pyramidal side-effects caused by many antipsychotics. The investigated azecines displayed low cytotoxicity, and the affinities for human dopamine D₁-D₅ and serotonin 5-HT_2 A receptors were in a nanomolar range. In vivo, their antipsychotic activities in the rat model were comparable with those of haloperidol and risperidone, but revealed a 2–5 times better therapeutic range with regard to catalepsy. Preliminary tests for oral bioavailability also revealed promising results for this new class of potential antipsychotic compounds. In conclusion, our in vivo experiments show that aromatic [d,g]-annelated azecines represent a novel and advantageous class of potential atypical neuroleptics.

Key words

5-HT_2 A receptor - dopamine receptor - azecine - antipsychotic - neuroleptic potency - catalepsy

• References

• 1 Knable MB, Egan MF, Heinz A et al. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study. Br J Psychiatry 1997; 171: 574-577
• 2 Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005; 20: 15-27
• 3 Moller HJ. Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl. 04) 99-107
• 4 Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl. 04) 90-98
• 5 Kehne JH, Baron BM, Carr AA et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996; 277: 968-981
• 6 Kleven M, Prinssen EP, Koek W. Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 1996; 313: 25-34
• 7 Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246
• 8 Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002; 453: 217-221
• 9 Wadenberg MG, Browning JL, Young KA et al. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 2001; 68: 363-370
• 10 Witt T, Hock FJ, Lehmann J. 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. J Med Chem 2000; 43: 2079-2081
• 11 Kassack MU, Hofgen B, Decker M et al. Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 543-550
• 12 Mohr P, Decker M, Enzensperger C et al. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. J Med Chem 2006; 49: 2110-2116
• 13 Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 1982; 51: 321-329
• 14 Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci Biobehav Rev 1999; 23: 851-862
• 15 Hoefgen B, Decker M, Mohr P et al. Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist. J Med Chem. 2006. 49. 760-769
• 16 Robaa D, Kretschmer R, Siol O et al. Residues at the indole-NH of LE300 modulate affinities and selectivities for dopamine receptors. Arch Pharm (Weinheim) 2010; 344: 28-36
• 17 Schulze M, Muller FK, Mason JM et al. Dibenzazecine scaffold rebuilding – is the flexibility always essential for high dopamine receptor affinities?. Bioorg Med Chem 2009; 17: 6898-8907
• 18 Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108
• 19 Rasmussen TH, Nielsen JB. Critical parameters in the MCF-7 cell proliferation bioassay (E-Screen). Biomarkers 2002; 7: 322-336
• 20 Becker A, Grecksch G. Phosphodiesterase inhibitors – are they potential neuroleptic drugs?. Behav Brain Res 2008; 186: 155-160
• 21 Kuribara H, Tadokoro S. Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav 1981; 14: 181-192
• 22 Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121-124
• 23 Chouinard G, Jones B, Remington G et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
• 24 Balsara JJ, Jadhav JH, Chandorkar AG. Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology (Berl) 1979; 62: 67-69
• 25 Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection?. Psychopharmacology (Berl) 1996; 124: 35-39
• 26 Davis KL, Kahn RS, Ko G et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-1486
• 27 Enzensperger C, Muller FK, Schmalwasser B et al. Dopamine/serotonin receptor ligands. 16.(1) Expanding dibenz[d,g]azecines to 11- and 12-membered homologues. Interaction with dopamine D(1)-D(5) receptors. J Med Chem 2007; 50: 4528-4533
• 28 National_Institute_of_Mental_Health NIMH PDSP database.‘[Internet]’ 2010 Available from: http://pdsp.med.unc.edu/